Diabetes drug shows promise in Parkinson disease
Nature Reviews Drug Discovery 16, 593 (2017).
doi:10.1038/nrd.2017.175
Author: Asher Mullard
There are no approved disease-modifying drugs for Parkinson disease, a neurodegenerative condition that affects 2–3% of people aged ≥65 years. Accumulating evidence suggests that GLP1 receptor agonists — incretin mimetics that researchers first developed for the treatment of diabetes — may have neuroprotective properties. A
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
More News: Brain | Diabetes | Drugs & Pharmacology | Endocrinology | Incretin Therapy | Neurology | Parkinson's Disease